PLU
MRVI icon

Performa Ltd (US)’s Maravai LifeSciences MRVI Stock Holding History

Performa Ltd (US)’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5K Sell
2,000
-750
-27% -$3.24K ﹤0.01% 31
2026
Q1 		$7.78K Sell
2,750
-564
-17% -$1.91K ﹤0.01% 34
2025
Q4 		$10.8K Sell
3,314
-13,336
-80% -$44.9K ﹤0.01% 26
2025
Q3 		$47.8K Sell
16,650
-6,340
-28% -$16.2K 0.01% 18
2025
Q2 		$55.4K Buy
22,990
+5,740
+33% +$12.1K 0.02% 19
2025
Q1 		$38.1K Buy
17,250
+12,250
+245% +$48.4K 0.01% 20
2024
Q4 		$27.3K Buy
5,000
+4,300
+614% +$27.7K 0.01% 23
2024
Q3 		$5.82K Buy
700
+450
+180% +$3.89K ﹤0.01% 34
2024
Q2 		$1.79K Sell
250
-6,500
-96% -$56.1K ﹤0.01% 47
2024
Q1 		$58.5K Buy
6,750
+750
+13% +$5.07K 0.03% 21
2023
Q4 		$39.3K Buy
6,000
+3,175
+112% +$20.5K 0.02% 23
2023
Q3 		$28.3K Buy
2,825
+825
+41% +$9.06K 0.01% 24
2023
Q2 		$24.9K Buy
2,000
+200
+11% +$2.7K 0.01% 26
2023
Q1 		$25.2K Buy
1,800
+300
+20% +$4.31K 0.01% 26
2022
Q4 		$21.5K Buy
1,500
+1,250
+500% +$19.7K 0.01% 29
2022
Q3 		$6K Buy
250
+200
+400% +$5.02K ﹤0.01% 45
2022
Q2 		$1K Buy
+50
New +$1.58K ﹤0.01% 63

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Performa Ltd (US)'s MRVI Position: Q2 2026 in Review

Performa Ltd (US) reduced its Maravai LifeSciences (MRVI) stake by 27% in Q2 2026, selling an estimated $3.24K and leaving 2,000 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #31.

Performa Ltd (US) first reported a position in MRVI in Q2 2022 and has held it in 17 quarters since. The position peaked at $58.5K in Q1 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Performa Ltd (US) held 2,000 shares of Maravai LifeSciences worth $12.5K as of Q2 2026.
  • Performa Ltd (US) sold 750 Maravai LifeSciences shares in Q2 2026, an estimated $3.24K.
  • Maravai LifeSciences made up ﹤0.01% of Performa Ltd (US)'s portfolio in Q2 2026, its #31 holding.
  • Performa Ltd (US) first reported a position in Maravai LifeSciences in Q2 2022 and has held it in 17 quarters since.
  • Performa Ltd (US)'s Maravai LifeSciences position peaked at $58.5K in Q1 2024.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Performa Ltd (US)'s 13F filing for Q2 2026, filed 3 Aug 2026.